These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7599336)

  • 21. [Inhibition of signal transduction pathways of endothelin-1-induced proliferation of vascular smooth muscle cells by nitric oxide].
    Zheng HZ; An GS; Nie SH; Tang CS; Liu NK; Wang SH
    Sheng Li Xue Bao; 1998 Aug; 50(4):379-84. PubMed ID: 11324546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide infusion alleviates cellular activation during preparation, leukofiltration and storage of platelets.
    Wong K; Li X
    Transfus Apher Sci; 2004 Feb; 30(1):29-39. PubMed ID: 14746819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
    Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
    Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oxidizing and reducing agents on ovine pulmonary artery responses to nitric oxide donors, sodium nitroprusside and 3-morpholino-sydnonimine.
    Sardar KK; Sarkar SN; Bawankule DU; Mishra SK; Raviprakash V
    Indian J Exp Biol; 2006 Dec; 44(12):964-70. PubMed ID: 17176668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered nitric oxide production and exogenous nitric oxide do not affect the proliferation of rat mesangial cells.
    Mohaupt M; Schoecklmann HO; Schulze-Lohoff E; Sterzel RB
    J Hypertens; 1994 Apr; 12(4):401-8. PubMed ID: 8064164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation.
    Pihusch V; Pihusch M; Penovici M; Kolb HJ; Hiller E; Pihusch R
    Thromb Res; 2005; 116(3):233-40. PubMed ID: 15935832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct electrochemical measurement of nitric oxide released from human platelets.
    Malinski T; Radomski MW; Taha Z; Moncada S
    Biochem Biophys Res Commun; 1993 Jul; 194(2):960-5. PubMed ID: 8343175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mode of cytostatic action of mesoionic oxatriazole nitric oxide donors in proliferating human hematopoietic cells.
    Vilpo JA; Vilpo LM; Vuorinen P; Moilanen E; Metsä-Ketelä T
    Anticancer Drug Des; 1997 Mar; 12(2):75-89. PubMed ID: 9113063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
    Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
    Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease.
    Simpson AJ; Booth NA; Moore NR; Bennett B
    Br J Haematol; 1990 Aug; 75(4):543-8. PubMed ID: 2207005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives.
    Kankaanranta H; Rydell E; Petersson AS; Holm P; Moilanen E; Corell T; Karup G; Vuorinen P; Pedersen SB; Wennmalm A; Metsä-Ketelä T
    Br J Pharmacol; 1996 Feb; 117(3):401-406. PubMed ID: 8821526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the slow in vitro inhibition of tissue plasminogen activator in plasma and platelet lysates.
    Felding P; Nilsson IM
    Thromb Haemost; 1989 Jun; 61(3):539. PubMed ID: 2508262
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of venous occlusion on the PAI and antiplasmins release from platelets.
    Woods AI; Nadra CA; Lazzari MA
    Thromb Res; 1989 Nov; 56(3):491-5. PubMed ID: 2515615
    [No Abstract]   [Full Text] [Related]  

  • 35. Distribution of plasminogen activator inhibitor (PAI-1) in tissues.
    Simpson AJ; Booth NA; Moore NR; Bennett B
    J Clin Pathol; 1991 Feb; 44(2):139-43. PubMed ID: 1864986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release of plasminogen activator by molsidomine and its active metabolite SIN-1.
    Klöcking HP; Hoffmann A; Markwardt F
    Pharmazie; 1987 May; 42(5):354. PubMed ID: 3671454
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of SIN-1 on the oxygenated metabolism of arachidonic acid in blood platelets and endothelial cells].
    Lagarde M; Croset M; Bordet JC
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):216-7. PubMed ID: 3550640
    [No Abstract]   [Full Text] [Related]  

  • 38. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma.
    Andrén-Sandberg A; Lecander I; Martinsson G; Astedt B
    Cancer; 1992 Jun; 69(12):2884-7. PubMed ID: 1591681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Release of plasminogen activator by SIN-1].
    Kloecking HP; Hoffmann A; Markwardt F
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):231-2. PubMed ID: 3104866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit.
    Mayer EJ; Fujita T; Gardell SJ; Shebuski RJ; Reilly CF
    Blood; 1990 Oct; 76(8):1514-20. PubMed ID: 2207327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.